HUNTINGTON’S DISEASE THERAPEUTICS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Huntington's Disease Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as -

> Alnylam Pharmaceuticals, Inc.
AmpliPhi Biosciences Corp.
Ceregene, Inc.
Cortex Pharmaceuticals, Inc.
Intellect Neurosciences Incorporation
Prana Biotechnology Limited


Click here to request a full list of companies covered in the report...

Code : MCP-6280
Price : $4500
Companies : 35
Pages : 123
Date : June 2013
Market Data Tables : 13

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS


 
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Prelude.....II-1
Huntington’s Disease – Few Quick Facts.....II-1
1$100
   Market Opportunity.....II-21$100
   Competition in the Global HD Therapeutics Market is Nonexistent.....II-3
Effectiveness of Current HD Management Strategies.....II-3
1$100
   HD Treatment and Drugs.....II-41$100
   Alternative Treatment Approaches for Huntington’s disease.....II-5
Alternate Approaches and Therapies.....II-5
Off-Label Prescriptions.....II-5
1$100
   Select Off-Label Drugs Prescribed for Huntington’s Disease.....II-61$100
   Companies Boost R&D Spending for HD Therapeutics.....II-7
Improved Diagnostics Fueling Interest of Companies in HD Research.....II-7
Support Organizations Play an Instrumental Role in HD Research and Awareness.....II-7
1$100
   Public-Private Partnerships: A Shot in the Arm.....II-8
HD Research Attracts 'Big Pharma' Investment.....II-8
Pre-Symptomatic Patients to Expand Market Base.....II-8
1$100
   HDSA Pushes for Improvement in Medicare Funding for Huntington’s Disease.....II-9
GINA for Reducing Discrimination Faced by People with HD.....II-9
2$200
   A Quick Primer.....II-11
Drug Development Pipeline Reveals Promising Picture.....II-11
Select Drugs and Supplements in HD Research Pipeline (2011).....II-11
2$200
   Overview of Select Pipeline Drugs.....II-13
Huntexil™ (Pridopidine).....II-13
RP103 (DR Cysteamine).....II-13
1$100
   PBT2.....II-14
Other Novel Approaches for HD Treatment.....II-14
Cellular Delivery of Neurotropic Agents.....II-14
Cogane.....II-14
1$100
   COPREXA.....II-15
Histone Deacetylases (HDAC).....II-15
Melatonin, Coenzyme Q-Free Radical Scavengers.....II-15
RNAi - RNA Interference.....II-15
1$100
   Small Molecule Inhibitor of Polyglutamine Interaction.....II-16
TELOMICS™.....II-16
1$100
   Lund University Researchers Successfully Map Functionality of Hypothalamus in
  HD.....II-17
MIB, University of Lisbon and University of Leicester Demonstrate Latest Findings on
  KMO Enzyme.....II-17
Latest TRACK-HD Findings Demonstrate Early Identification of Huntington's Disease
  Progression in Patients.....II-17
1$100
   Researchers at BUSM, MGH, Columbia University and McLean BTRC Demonstrate Impact of
  Huntington's Disease on Human Brain.....II-18
Researchers Demonstrate Significance of TFEB and PGC-1alpha Proteins in Prevention of
  HD.....II-18
1$100
   Florey Neuroscience Institutes Demonstrates Importance of Cognitive Stimulation in
  HD Patients.....II-19
University of Wisconsin-Madison Waisman Center Demonstrates Stem Cell Therapy
  Potential for Treating HD.....II-19
NUI Galway Announces Discovery of Experimental Drugs with Potential for Slowing
  Progress of HD.....II-19
1$100
   Lawrence Berkeley National Laboratory Designs Compound for Suppressing HD
  Symptoms.....II-20
Development of HD Affected Human Brain Cells for Investigative Purposes.....II-20
Device Implant in Brain Exhibits Therapeutic Potential for HD.....II-20
1$100
   Sangamo Biosciences on Path to Discover a Therapy for HD.....II-21
Scientists at University of Rochester Medical Center Demonstrate Use of Coenzyme Q10
  for Reduction of Oxidative Damage in HD Patients.....II-21
1$100
   McMaster University Discovers New Drug Candidate for Huntington's Disease.....II-22
University of Central Florida Researchers Test Role of DRP1 Protein in HD.....II-22
1$100
   CMMT and Brain Research Centre Decode Cellular Mechanism Related to Alteration of
  Brain Cell Function in HD.....II-23
1$100
   Introduction.....II-24
Historical Background.....II-24
1$100
   Prognosis.....II-25
Stages of HD.....II-25
1$100
   Symptoms and Signs.....II-26
Physical Symptoms.....II-26
1$100
   Emotional Symptoms.....II-27
Mental Symptoms.....II-27
Genetics of Huntington's Disease.....II-27
1$100
   Inheritance.....II-28
Mechanism.....II-28
1$100
   Functions of HTT.....II-29
Effects of mHTT on Cells.....II-29
Macroscopic Effects of mHTT.....II-29
1$100
   Diagnosis of HD.....II-30
Clinical Diagnosis.....II-30
Embryonic Diagnosis.....II-30
1$100
   Differential Diagnosis.....II-31
Diagnostic Tests for Huntington's Disease.....II-31
Confirmatory Diagnostic Test.....II-31
Pre-symptomatic Diagnostic Test.....II-31
Prenatal Diagnostic Test.....II-31
Treatment Options.....II-31
Nutrition and Eating.....II-31
1$100
   Social Activity.....II-32
Speech Therapy.....II-32
Physical Therapy.....II-32
1$100
   Occupational Therapy.....II-33
Medication.....II-33
1$100
   Dimebon Fails Horizon Trials for Treatment of Cognitive Dysfunction in HD
  Patients.....II-34
Huntexil’s Trials Prove only Borderline Benefits.....II-34
AFQ056 in Phase II Clinical Study for Treatment of Chorea.....II-34
1$100
   Siena Biotech S.p.A. Undertakes Preparatory Steps for Phase II study of
  SEN0014196.....II-35
Elontril in the Set-up Stage for Phase II Study.....II-35
Alnylam Presents Positive Pre-clinical Data for its siRNA for silencing the Mutant
  HTT.....II-35
1$100
   Roche Enters into Alliance with Isis Pharmaceuticals.....II-36
Isis and CHDI Collaborate with KineMed.....II-36
1$100
   Omeros Receives IND Approval for OMS824 for Huntington’s Disease.....II-371$100
   Teva Pharmaceutical Industries Signs Asset Transfer Agreement with NeuroSearch.....II-38
uniQure and Benitec Biopharma Ink Cross- Licensing Agreement.....II-38
Evotec and CHDI Foundation Extend Collaboration.....II-38
Raptor Acquires Exclusive Rights to Cysteamine and Associated Compounds.....II-38
1$100
   GNS Healthcare Enters into Collaboration with CHDI Foundation.....II-39
Lundbeck Collaborates with CHDI Foundation for HD Research.....II-39
1$100
   Horizon Discovery Collaborates with Institute of Neurology, London.....II-40
Thomson Reuters and CHDI Foundation Enter into MetaMiner Partnership.....II-40
Targeted Genetics Changes Name to AmpliPhi Biosciences.....II-40
1$100
   Intellect Neurosciences Commences Initial Development of CONJUMAB-A Platform
  Technology.....II-41
CHDI Foundation and Galenea Collaborate.....II-41
CHDI Foundation and Isis Pharmaceuticals Renew Collaboration.....II-41
1$100
   Sage Bionetworks and Takeda Pharmaceutical Enter into Research Alliance.....II-42
Sage Bionetworks Extends Partnership with CHDI Foundation.....II-42
1$100
   University of Dundee and GlaxoSmithKline to Collaborate over HD Research.....II-431$100
   Gladstone Institute and Taube-Koret to Collaborate with Institute for Systems
  Biology.....II-44
Alliance Pharma Concludes Distribution Deal with Biovail.....II-44
Lundbeck Acquires LifeHealth.....II-44
Lundbeck Acquires Ovation.....II-44
1$100
   Biovail Purchases Global Rights for Tetrabenazine from Cambridge.....II-45
Raptor Pharmaceuticals, TorreyPines Conclude Merger.....II-45
Cambridge Laboratories Enters into New Agreements for Marketing Xenazine® in North
  America.....II-45
CHDI Foundation Inks Agreement with AMRI for Drug Discovery.....II-45
1$100
   Phytopharm Inks Agreement with CHDI Foundation to Evaluate Cogane.....II-46
NeuroSearch Repurchases Global Rights to ACR16.....II-46
Raptor Pharmaceuticals Enters into Collaboration with Centre Hospitalier Universitaire
  d'Angers for Phase II Clinical Trial.....II-46
1$100
   Targeted Genetics Acquires Full Rights from Sirna Therapeutics to siRNA Development
  Program.....II-47
Cambridge Laboratories Receives Marketing Approval for Tetrabenazine from Agencia
  Espanola de Medicamentos y Productos Sanitarios.....II-47
1$100
   Cambridge Laboratories Inks and Renews Agreements with Taiwan, New Zealand, Finland
  and Australia.....II-48
CHDI Inked Collaboration Agreements with Galapagos.....II-48
Biovail Acquires Prestwick Pharmaceuticals.....II-48
1$100
   Ovation Pharmaceuticals Acquires License to Commercialize Xenazine® in the US.....II-49
Aegera Therapeutics Inks License Agreement with Neurologix.....II-49
1$100
   Alnylam Pharmaceuticals, Inc. (US).....II-50
AmpliPhi Biosciences Corp (US).....II-50
Ceregene, Inc. (US).....II-50
1$100
   Cortex Pharmaceuticals, Inc. (US).....II-51
Intellect Neurosciences Incorporation (US).....II-51
1$100
   Prana Biotechnology Limited (Australia).....II-52
Raptor Pharmaceuticals Corp. (US).....II-52
1$100
   Teva Pharmaceutical Industries Ltd (Israel).....II-53
Trophos SA (France).....II-53
1$100
   Valeant Pharmaceuticals International, Inc. (Canada).....II-54
Vertex Pharmaceuticals Incorporated (US).....II-54
1$100
   Table 1: Global Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart).....II-551$350
   Table 2: World 10-Year Perspective for Huntington’s Disease Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, and Rest of World Markets for Years 2009, 2013 & 2018 (includes corresponding Graph/Chart).....II-561$350
   A. Market Analysis.....III-1
Outlook.....III-1
HDSA Pushes for Improvement in Medicare Funding for Huntington’s Disease.....III-1
1$90
   GINA for Reducing Discrimination Faced by People with HD.....III-2
Strategic Corporate Developments.....III-2
5$450
   Select Players.....III-73$270
   B. Market Analytics.....III-10
Table 3: The US Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart).....III-10
1$200
   A. Market Analysis.....III-11
Outlook.....III-11
B. Market Analytics.....III-11
Table 4: European Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - France, Germany, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart).....III-11
1$200
   Table 5: European 10-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Dollar Revenues for France, Germany, UK, Spain and Rest of Europe Markets for Years 2009, 2013 & 2018 (includes corresponding Graph/Chart).....III-121$200
   A. Market Analysis.....III-13
Outlook.....III-13
Trophos SA – A Key Player.....III-13
1$90
   B. Market Analytics.....III-14
Table 6: French Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart).....III-14
1$200
   A. Market Analysis.....III-15
Outlook.....III-15
Strategic Corporate Development.....III-15
1$90
   B. Market Analytics.....III-16
Table 7: German Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart).....III-16
1$200
   A. Market Analysis.....III-17
Outlook.....III-17
Table 8: Juvenile HD Incidence Estimates in the UK (includes corresponding Graph/Chart).....III-17

Table 9: Juvenile HD Prevalence Estimates in the UK (2006-2010) (includes corresponding Graph/Chart).....III-17
1$200
   Strategic Corporate Developments.....III-181$90
   B. Market Analytics.....III-19
Table 10: The UK Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart).....III-19
1$200
   A. Market Analysis.....III-20
Outlook.....III-20
B. Market Analytics.....III-20
Table 11: Spanish Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart).....III-20
1$200
   A. Market Analysis.....III-21
Outlook.....III-21
Strategic Corporate Development.....III-21
1$90
   B. Market Analytics.....III-22
Table 12: Rest of Europe Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart).....III-22
1$200
   A. Market Analysis.....III-23
Outlook.....III-23
Strategic corporate development.....III-23
Select players.....III-23
2$180
   B. Market Analytics.....III-25
Table 13: Rest of World Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart).....III-25
1$200
  
Total Companies Profiled: 35 (including Divisions/Subsidiaries - 36)

Region/Country Players

The United States 18 Canada 2 Europe 13 France 1 Germany 1 The United Kingdom 3 Italy 1 Rest of Europe 7 Asia-Pacific (Excluding Japan) 2 Middle East 1
Click here to request a full table of contents and more details on this project.